Nombre del producto:4-Amino-2-hydroxy-5-methylpyridine

IUPAC Name:4-amino-5-methyl-1,2-dihydropyridin-2-one

CAS:95306-64-2
Fórmula molecular:C6H8N2O
Pureza:98%
Número de catálogo:CM120752
Peso molecular:124.14

Unidad de embalaje Stock disponible Precio($) Cantidad
CM120752-100g in stock ǤNJʼn

Sólo para uso en I+D..

Formulario de consulta

   refresh    

Detalles del producto

Núm. De CAS :95306-64-2
Fórmula molecular:C6H8N2O
Punto de fusión:-
Código de sonrisas:O=C1C=C(N)C(=CN1)C
Densidad:
Número de catálogo:CM120752
Peso molecular:124.14
Punto de ebullición:
Nº Mdl:MFCD18384902
Almacenamiento:Keep in dark place, store at 2-8°C.

Category Infos

Pyridines
Pyridine is a six-membered heterocyclic compound containing one nitrogen heteroatom. Pyridine and piperidine are the most frequently occurring heterocyclic building blocks in drug molecules. According to incomplete statistics, there are currently more than 180 drugs containing pyridine or piperidine structure that have been marketed, nearly 1/5 of the drugs approved for marketing in recent years contain these two structures.
Pyridine | C5H5N | Pyridine Supplier/Distributor/Manufacturer - Chemenu
Pyridine,Pyridine Wholesale,Pyridine for Sale,Pyridine Supplier,Pyridine Distributor,Pyridine Manufacturer
Pyridine is a basic heterocyclic organic compound with the chemical formula C5H5N. It is structurally related to benzene, with one methine group (=CH−) replaced by a nitrogen atom. It is a highly flammable, weakly alkaline, water-miscible liquid with a distinctive, unpleasant fish-like smell.

Column Infos

Finerenone
Bayer announced that FINEARTS-HF met its primary endpoint, achieving a statistically significant reduction of the composite of cardiovascular death and total (first and recurrent) heart failure (HF) events, defined as hospitalizations for HF or urgent HF visits. The randomized, double-blind, placebo-controlled, parallel-group, multi-center phase III cardiovascular outcomes study evaluated the efficacy and safety of KERENDIA® (finerenone) for investigational new use in patients with HF with a LVEF≥40% (left ventricular ejection fraction). Finerenone is a nonsteroidal mineralocorticoid receptor antagonist (MRA) that was approved to reduce the risk of cardiovascular death, non-fatal myocardial infarction, hospitalization for heart failure, sustained eGFR decline, and end-stage kidney disease in adult patients with CKD associated with T2D.
Chemenu has been working to develop more compounds for drug discovery. Here are the building blocks we can provide.